bioRxiv / medRxiv
open access
mTOR disrupts cerebrovascular RNA regulatory networks in Alzheimers disease
Cerebrovascular dysfunction is increasingly recognized as a central contributor to the initiation and progression of Alzheimer's disease (AD). The mammalian/mechanistic target of rapamycin (mTOR) pathway has emerged as a key driver of AD-related vascular dysfunction. Consistent with this role, atten
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis#948961
- High-Throughput Screening Identifies Small-Molecule Inhibitors of the Tau-LRP1 Interaction#1149577
- Endothelial RRM2B-dependent mitochondrial DNA signalling drives doxorubicin-cardiotoxicity#273205
- Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome#948442
- Computational Analysis of FDA-Approved Drugs for Potential Repurposing in Alzheimer's Disease: Targeting mTOR and NGFR Pathways#320931
Record · ID 1349070
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive